41. Giant cell arteritis Clinical trials / Disease details


Clinical trials : 128 Drugs : 139 - (DrugBank : 36) / Drug target genes : 33 - Drug target pathways : 124

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-000622-26-DE
(EUCTR)
22/01/202117/09/2020A Proof-of-Concept Study of Guselkumab in the Treatment of Subjects with New-Onset or Relapsing Giant Cell ArteritisA Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Participants with New-Onset or Relapsing Giant Cell Arteritis - THEIA Giant Cell Arteritis
MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 10047065 - Vascular disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Guselkumab
Product Code: CNTO1959
INN or Proposed INN: Guselkumab
Product Name: Guselkumab
Product Code: CNTO1959
INN or Proposed INN: Guselkumab
Janssen-Cilag International N.V.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Phase 2United States;France;Canada;Spain;Poland;Belgium;Israel;Germany;Italy
2EUCTR2020-000622-26-IT
(EUCTR)
18/12/202024/05/2021A Proof-of-Concept Study of Guselkumab in the Treatment of Subjects with New-Onset or Relapsing Giant Cell ArteritisA Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Participants with New-Onset or Relapsing Giant Cell Arteritis - THEIA Giant Cell Arteritis
MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 10047065 - Vascular disorders;Therapeutic area: Diseases [C] - Virus Diseases [C02]
Product Name: Guselkumab
Product Code: [CNTO1959]
INN or Proposed INN: GUSELKUMAB
Other descriptive name: * D.3.6.2.1 - valore :Every 4 weeks dosing of 400 mg
Product Name: Guselkumab
Product Code: [CNTO1959]
INN or Proposed INN: GUSELKUMAB
Other descriptive name: * D.3.6.2.1 - valore : Every 4 weeks dosing of 200 mg
JANSSEN CILAG INTERNATIONAL NVNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Phase 2France;United States;Canada;Spain;Poland;Belgium;Germany;Italy
3NCT04633447
(ClinicalTrials.gov)
December 10, 20206/11/2020A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell ArteritisA Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell ArteritisGiant Cell ArteritisDrug: Guselkumab;Drug: PlaceboJanssen Research & Development, LLCNULLRecruiting50 YearsN/AAll60Phase 2United States;Belgium;Canada;France;Germany;Israel;Italy;Poland;Spain